Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Baclofen may be a useful therapy in GERD

Treating GERD patients with baclofen for 1 month reduces esophageal acid reflux and improves symptoms, claim researchers reporting to DDW 2002.

News image

fiogf49gjkf04

A team from Pescara, Italy, assessed the effects of 1-month treatment with baclofen, a gamma-aminobutyric acid (GABAB) agonist, in patients with gastroesophageal reflux disease (GERD).

They presented their findings at Digestive Diseases Week 2002, held this week in San Francisco, California, USA.

Previous studies have shown that short-term administration of baclofen, for 24 hours, reduces reflux episodes in GERD patients and in controls.

The researchers assessed its effect on 24-hour pH-metry and symptoms before and after the treatment.

A total of 14 GERD patients were included in the study.

At entry all patients underwent a 24-hour esophageal pH-metry.

In addition, they completed a questionnaire on various symptoms, including bitter taste, belching, fasting epigastric pain, post-prandial epigastric pain, nocturnal epigastric pain, heartburn, regurgitation, and dysphagia.

The intensity and frequency of each symptom were scored from 0 to 4.

Mean number of reflux episodes:
Before baclofen: 257
After treatment: 54
DDW

Patients were randomly assigned to receive baclofen (10 mg orally, four times daily [n = 10]) or placebo (n = 4).

The authors then re-evaluated 24-hour pH-metry and total symptoms score at the end of treatment.

In each recording, the pH was analyzed for total number of acid reflux and percentage of time with pH < 4 in the esophagus.

Two patients in the baclofen group dropped out during treatment due to nocturna dyspnea and slight hypotension.

The mean number of reflux episodes was significantly lower after treatment with baclofen (257 before baclofen, 54 after baclofen).

Furthermore, the percentage of time with pH < 4, was also significantly lower after treatment with baclofen (6% before baclofen, 3% after baclofen).

There was no difference in reflux episodes and in percentage of time with pH < 4 after treatment in the 4 patients treated with placebo.

The researchers found that the intensity and frequency of symptoms were both significantly improved after treatment with baclofen (mean total symptoms score: intensity 1.7 before baclofen, 0.4 after; frequency 2.2 before baclofen, 0.4 after).

However, there was no difference in intensity and frequency of the symptom score after treatment with placebo.

Dr Antonio Francesco Ciccaglione said on behalf of his colleagues, "Baclofen, given for 1 month, reduces esophageal acid reflux and significantly improves symptoms in patients with GERD.

"These results suggest that baclofen may be a useful therapy in GERD", he concluded.

DDW
21 May 2002

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us